Background: Topical corticosteroids are the mainstay of psoriasis treatment, with long-term safety considerations limiting their use. Combining them with tazarotene may optimize their efficacy and minimize safety and tolerability concerns.
Limitations: Studies did not include subjects with more than 12% of their body surface area affected by psoriasis.
Conclusions: HP/TAZ lotion was associated with significant reductions in the severity of the clinical signs of psoriasis, with no safety concerns. ( J Am Acad Dermatol 2018;79:287-93.)
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Topical therapy is a key component of psoriasis management; it is considered first-line therapy for mild disease and is often used alone or in conjunction with systemic agents in more severe psosiasis. 1 Use of topical corticosteroids (TCSs) is commonplace, mainly because of their immunosuppressive, antiinflammatory, and antiproliferative properties. However, long-term safety concerns remain, particularly with more potent formulations, owing to an increased risk of local cutaneous adverse events (AEs). [1] [2] [3] Consequently, TCSs such as halobetasol propionate cream (Ultravate 0.05%, Ranbaxy Laboratories, Inc, Jacksonville, FL) are not recommended for more than 2 consecutive weeks' use.
Tazarotene has also been shown to be effective in psoriasis, 4 ,5 but it's use is limited by irritancy. Studies suggest that combination with TCSs may optimize the efficacy of, duration of remission resulting from, and safety of TCS treatment in addition to minimizing local irritation due to tazarotene. [6] [7] [8] Use of fixed combination topical treatments in dermatology can provide synergistic therapeutic efficacy and tolerability benefits. Development of the formulation is key in attaining the balance between efficacy and safety; vehicles can significantly affect efficacy and adherence and increase cosmetic elegance. 9 Recently, phase 2 clinical data on 8 weeks' treatment of moderate-to-severe psoriasis with a novel halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion formulation were published. 10 HP/TAZ lotion was significantly more effective than the individual active ingredients or vehicle, and it was well tolerated. Here, we have further investigated the safety and efficacy of HP/TAZ lotion, reporting on 2 phase 3 clinical studies.
METHODS

Study design
Two multicenter, doubleblind, randomized, parallelgroup phase 3 studies were conducted to assess the safety, tolerability, and efficacy of HP/TAZ lotion in subjects with moderate-tosevere psoriasis.
The studies, which were registered on ClinicalTrials. gov as NCT02462070 and NCT02462122, were conducted at 32 clinical sites in the United States from August 2015 to November 2016.
Subjects and randomization
For inclusion, subjects could be of either sex but had to be age 18 years or older and have moderateto-severe plaque psoriasis with an Investigator Global Assessment (IGA) score of 3 or 4 and affected body surface area (BSA) of 3% to 12%.
Subjects were randomized (2:1) to HP/TAZ lotion or vehicle applied topically to the affected area once daily for 8 weeks, with initial application at the investigational center. Subjects were instructed to spread a thin layer over the affected area and avoid ultraviolet radiation (natural and artificial). The maximum allowable weekly use was 50 g.
Assessments were carried out at baseline; at weeks 2, 4, 6, and 8 of treatment; and at 4 weeks after treatment (week 12).
Study oversight
Subjects provided written informed consent; protocol and consent were approved by institutional review boards or ethics committees at all investigational sites. Investigators were trained for
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consistency, sites were monitored for protocol compliance, and the studies were conducted in accordance with the principles of Good Clinical Practice and the Declaration of Helsinki.
Statistical and analytical plan
The primary efficacy assessment end point was difference in treatment effect between HP/TAZ lotion and vehicle with respect to IGA score. Statistical processing was performed with SAS software (SAS Institute Inc, Cary, NC) unless otherwise stated; statistical tests were 2 sided and performed at the .05 significance level. Markov chain Monte Carlo multiple imputation was used to handle missing efficacy data.
All subjects who were randomized and received the study drug were included in the intent-to-treat analysis, which was primary for efficacy evaluation. Data were analyzed by using Cochran-MantelHaenszel tests stratified by analysis center. The Dermatology Life Quality Index (DLQI) results were summarized by using descriptive statistics; affected BSA was examined in a post hoc analysis of covariance with a factor of treatment and baseline affected BSA as a covariate.
The primary safety analysis was conducted at week 8 by using the safety analysis set (those who were randomized, received at least 1 confirmed dose of study drug, and received at least 1 postbaseline safety assessment). AEs were recorded and classified by using the Medical Dictionary for Regulatory Activities, Version 18.0. All reported treatmentemergent AEs were summarized by treatment group and relationship to the study drug. A safety analysis was also conducted at week 12. A post hoc Wilcoxon rank sum test was performed to compare itching, dryness, and burning/stinging scores at week 8 and week 12.
Study assessment
Efficacy. The primary efficacy end point was percentage of subjects who were treatment successes at week 8 (those with at least a 2-grade improvement from baseline IGA score and a score of clear or almost clear). IGA score was assessed by the investigator by using a 5-point scale ranging from 0 (clear) to 4 (severe) at each study visit. 10 Secondary efficacy data were provided at weeks 2, 4, 6, and 12.
Signs of psoriasis were assessed at each visit by using 5-point scales ranging from 0 (clear) to 4 (severe), 10 with treatment success being the percentage of subjects with at least a 2-grade improvement from baseline for each of key sign (erythema, plaque elevation, and scaling).
Affected BSA was assessed at each visit. The DLQI, a 10-item patient-reported questionnaire commonly used to assess health-related quality of life (QoL) in patients with chronic plaque psoriasis, 11 was administered at baseline and at weeks 4, 8, and 12.
Safety. Safety evaluations were performed. They included assessment of AEs, local skin reactions, and vital signs (at each visit); laboratory evaluations (at screening, week 8, and week 12), physical examinations (at baseline, week 8, and week 12), and electrocardiograms (study 1).
Local skin reactions. Local skin reactions were evaluated by assessing selected local signs and symptoms (itching, dryness, and burning/stinging) at each study visit by using 4-point scales ranging from 0 (clear) to 3 (severe). 10 Presence of local signs and symptoms at baseline is commonplace, and assessments highlighted both improvement and emergent issues.
Treatment areas were examined at each visit for presence or absence of the following significant known drug-related AEs: skin atrophy, striae, telangiectasia, and folliculitis.
RESULTS
Subject disposition
In both studies, 418 subjects were randomized to HP/TAZ lotion or vehicle (Fig 1) and included in the intent-to-treat population. Of the subjects, 84.1% (n = 232) and 83.1% (n = 118), respectively, completed the 2 studies. The main reasons for discontinuation were subject request (6.2% [n = 17] and 8.5% [n = 12] with HP/TAZ lotion and vehicle, respectively), AEs (4.0% [n = 11] and 2.8% [n = 4]), and loss to follow-up (3.3% [n = 9] and 4.2% [n = 6]). A total of 410 subjects were included in the safety population (there was no postbaseline safety evaluation in 8 subjects).
Demographics and baseline characteristics
Demographic data and baseline disease characteristics were comparable across the 2 studies. The mean ages were 48.8 (study 1) and 51.8 (study 2). The majority of subjects were male (65.1% [n = 272]) and white (85.6% [n = 358]). Efficacy evaluation IGA score. HP/TAZ lotion was consistently more effective than vehicle in achieving treatment success, demonstrating statistically significant superiority by week 2 (study 2) and week 4 (study 1). At week 8, 35.8% (study 1) and 45.3% (study 2) of those receiving HP/TAZ lotion had achieved this primary efficacy outcome (vs 7.0% and 12.5% of those receiving vehicle) (both P \.001) (Fig 2) .
The majority of subjects maintained treatment success over the 4-week post-treatment period. HP/TAZ lotion demonstrated sustained therapeutic success in 33.3% (study 1) and 33.4% (study 2) of subjects (vs 8.5% and 8.8% in those who were receiving vehicle) (both P \.001).
Signs of severity of psoriasis. HP/TAZ lotion was superior to vehicle in reducing erythema, plaque elevation, and scaling, with sustained efficacy after treatment. At week 8, treatment success was achieved by 44.2% and 49.6% (erythema in study 1 and study 2, respectively), 59.3% and 59.7% (plaque elevation), and 59.4% and 62.9% (scaling) of subjects treated with HP/TAZ lotion (vs 10.0% and 18.7%, 17.9% and 21.3%, and 20.6% and 21.0% of those receiving vehicle in study 1 and study 2, respectively) (P \ .001) (Fig 3) . HP/TAZ lotion demonstrated sustained therapeutic success in 45.8% and 41.2% (erythema in study 1 and study 2, respectively), 56.4% and 46.7% (plaque elevation), and 52.5% and 46.9% (scaling) of subjects treated with HP/TAZ lotion (vs 16.6% and 16.2%, 26.3% and 18.2%, and 24.9% and 18.6% of those receiving vehicle, in study 1 and study 2, respectively) (all P \.001).
Affected BSA and DLQI score. HP/TAZ lotion was significantly more effective than vehicle in reducing affected BSA and more effective in reducing DLQI score. At week 8 there were 32.8% (study 1) and 42.5% (study 2) reductions in affected BSA (vs À2.3% and 8.3% with vehicle, respectively) (both P\.001) and 45.3% (study 1) and 54.5% (study 2) reductions in mean DLQI score (vs 30.1% and 32.5% with vehicle, respectively).
Safety evaluation
Of the subjects treated with HP/TAZ lotion, 35.9% reported AEs (compared with 21.4% of those treated with vehicle), with the majority of AEs (85.6%) being mild or moderate. The most common Investigator's Global Assessment (IGA) score for disease severity at each study visit. Subjects were categorized as treatment successes (defined as at least a 2-grade improvement from the baseline score and a score of clear or almost clear) (individual study data for the intentto-treat population). HP/TAZ, Halobetasol propionate plus tazarotene. Improvement in signs of psoriasisderythema, plaque elevation, and scalingdat each study visit in subjects who were treatment successes (defined as at least a 2-grade improvement from the baseline score) (individual study data for the intent-to-treat population). HP/TAZ, Halobetasol propionate plus tazarotene.
J AM ACAD DERMATOL treatment-related AEs were contact dermatitis (6.3%), pruritus (2.2%), and application site pain (2.6%). Skin atrophy, telangiectasia, or folliculitis were minimal, sporadic, and not consistent. Only 3 subjects reported serious AEs following treatment with HP/TAZ lotion (1.1%); none was treatment related (cellulitis, staphylococcal pneumonia/ asthma, and anemia).
Local skin reactions
Investigator-reported mild dryness and subjectreported mild-to-moderate itching and minimal burning/stinging were present at baseline. There was rapid and sustained improvement in itching by week 2 (a 54.2% reduction from baseline), with more gradual improvements in skin dryness and burning/ stinging. By week 8, the mean scores for itching, dryness, and burning/stinging were statistically significantly lower than those for vehicle (P = .002, .018, and .022, respectively) and had been reduced by 52.7%, 43.9%, and 45.6%, respectively (vs by 21.6%, 21.7%, and À8.2% with vehicle) (Fig 4) .
DISCUSSION
The rationale behind studying HP/TAZ lotion was to develop a topical treatment for moderate-tosevere psoriasis that would provide enhanced efficacy and reduce or minimize tazarotene's irritant effects and local cutaneous halobetasol-related AEs without the limitation of 2 weeks' consecutive use owing to the presence of halobetasol while having a light, aesthetically pleasing formulation that patients prefer.
Clinical studies have established the benefit of using TCSs as adjunctive therapy with tazarotene to treat plaque psoriasis. 7, 8, 12, 13 Data on the combined use of halobetasol and tazarotene are limited, but an early study with this combination demonstrated synergistic benefits over those of the individual active ingredients, with a much lower incidence of application site reactions when compared with that of tazarotene monotherapy. 10 In our investigation, treatment success was achieved in around 40% of subjects by week 8, with substantial reductions in affected BSA, improvement in QoL, and a significant reduction in signs and symptoms of psoriasis. The improvement was sustained, with the majority of subjects who achieved treatment success by week 8 maintaining efficacy after treatment, likely because of the influence of tazarotene. Rebound (worsening of disease following discontinuation of treatment) is not uncommon with TCSs but was not seen in our studies, most likely thanks to tazarotene, which induces a longer remission after treatment. 5, 7, 13 Ideally, psoriasis treatments should improve dry skin without exacerbating itching, burning, or stinging. Tazarotene use can exacerbate the problem, as it induces a dose-dependent local irritation with itching, burning, and erythema, which has limited its use in psoriasis.
14 HP/TAZ lotion provided significant, rapid improvements in baseline itching over the first 2 weeks (a 54% reduction by week 2) that were maintained over the studies' duration without any obvious deleterious effect from the tazarotene. In addition, skin dryness was improved by 44% and burning/stinging was reduced by 46% over the 8-week treatment period.
Physicians continue to have concerns over longterm safety with TCSs, 1,2,15 patients remain concerned about the risk of skin thinning, 16 and product labeling restricts halobetasol use to 2 weeks. There were minimal safety concerns in our 2 studies using an 8-week treatment regimen with HP/TAZ lotion.
HP/TAZ lotion was well tolerated. Irritant contact dermatitis was the most common AE and was likely the consequence of the tazarotene component, as it was also reported in the tazarotene arm of the phase 2 study. 10 In the majority of cases it was mild or moderate. The rate of pruritus was similar to the rate reported with vehicle (2.2% vs 2.9%). Application site pain was lower than that reported with HP/TAZ lotion (3.4%) or tazarotene (6.9%) in the phase 2 study. 10 
CONCLUSIONS
HP/TAZ lotion combines the benefits of both ingredients to provide synergistic outcomes. It was consistently more effective than vehicle in achieving treatment success, effectively reducing the affected area and signs of psoriasis at the target lesion, and improving QoL. There were minimal safety concerns with using an 8-week treatment duration, and the studies are currently being analyzed to assess longterm safety over 12 months.
